In Silico Analysis of HA2/Mx Chimera Peptide for Developing an Adjuvanted Vaccine to Induce Immune Responses Against Influenza Viruses

Soleimani, Sina; Madadgar, Omid; Shahsavandi, Shahla; Mahravani, Homayoon; Lotfi, Mohsen

doi:10.15171/apb.2015.085

Cited by 5 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, we assessed all combinations of antigens to find a combination that has most stable and natural state. Recently, in silico study on HA with another adjuvant called Mx fused by EAAK linker was carried out [26]. The difference between our study and the mentioned study is that we examined different types of adjuvants and selected the best one, not just one adjuvant, regardless of its effect on the vaccine's structural and physiochemical properties.…”

Section: Discussionmentioning

confidence: 97%

Designing a chimeric subunit vaccine for influenza virus, based on HA2, M2e and CTxB: a bioinformatics study

Jafari

Malih

Gomari

et al. 2020

BMC Mol and Cell Biol

View full text Add to dashboard Cite

Background Type A influenza viruses are contagious and even life-threatening if left untreated. So far, no broadly protective vaccine is available due to rapid antigenic changes and emergence of new subtypes of influenza virus. In this study, we exploited bioinformatics tools in order to design a subunit chimeric vaccine from the antigenic and highly conserved regions of HA and M2 proteins of H7N9 subtype of influenza virus. We used mucosal adjuvant candidates, including CTxB, STxB, ASP-1, and LTB to stimulate mucosal immunity and analyzed the combination of HA2, M2e, and the adjuvant. Furthermore, to improve the antigen function and to maintain their three-dimensional structure, 12 different linkers including six rigid linkers and six flexible linkers were used. The 3D structure model was generated using a combination of homology and ab initio modeling methods and the molecular dynamics of the model were analyzed, either. Results Analysis of different adjuvants showed that using CtxB as an adjuvant, results in higher overall vaccine stability and higher half-life among four adjuvant candidates. Fusion of antigens and the CTxB in the form of M2e-linker-CTxB-linker-HA2 has the most stability and half life compared to other combination forms. Furthermore, the KPKPKP rigid linker showed the best result for this candidate vaccine among 12 analyzed linkers. The changes in the vaccine 3D structure made by linker insertion found to be negligible, however, although small, the linker insertion between the antigens causes the structure to change slightly. Eventually, using predictive tools such as Ellipro, NetMHCpan I and II, CD4episcore, CTLpred, BepiPred and other epitope analyzing tools, we analyzed the conformational and linear epitopes of the vaccine. The solubility, proteasome cleavage sites, peptidase and potential chemical cutters, codon optimization, post translational modification were also carried out on the final vaccine. Conclusions It is concluded that M2e-Linker-CTxB-Linker-HA2 combination of chimeric vaccine retains its 3D structure and antigenicity when KPKPKP used as linker and CTxB used as adjuvant.

show abstract

Section: Discussionmentioning

confidence: 97%

Designing a chimeric subunit vaccine for influenza virus, based on HA2, M2e and CTxB: a bioinformatics study

Jafari

Malih

Gomari

et al. 2020

BMC Mol and Cell Biol

View full text Add to dashboard Cite

show abstract

“…The oligonucleotide coding sequence of the conserved SGKSSVLEALSGVALPR motif of Mx which was known to be effective in inducing B-cell and T-cell immune responses based on an in silico study [23] was selected. The coding sequence was constructed in pcDNA3.1 as described previously [11] and was used at final concentration of 10 μg/μl.…”

Section: Adjuvant Synthesismentioning

confidence: 99%

Combination of Chitosan and Myxovirus Resistance Oligonucleotide: An Efficient and Safe Natural Adjuvant against Influenza Virus

Ahmadi¹,

Tabar²,

شاهسوندی³

et al. 2020

vacres

Self Cite

View full text Add to dashboard Cite

Introduction: Avian influenza virus causes severe economic losses to the poultry industry and has a great potential for becoming a pandemic threat for humans. The application of natural adjuvants has opened up new avenues toward reaching a highly efficient and safe vaccine in recent years. In this study, we investigated the adjuvant activity of interferon-induced myxovirus resistance (Mx) protein on chitosan-based H9N2 nanoparticles in a BALB/c mouse model. Methods: The inactivated H9N2 virus antigen was encapsulated in chitosan nanoparticles (NPs) using gelation method. Female BALB/c mice were randomly divided into four groups (n=10). Group A received the H9N2-loaded chitosan NPs mixing with Mx intranasally and was boosted twice with a 1-week interval. Group B received the H9N2-loaded chitosan NPs in the same manner. Mice in groups C and D received the chitosan NPs and PBS, respectively as negative controls. Body weights of the mice were measured at defined times. Blood samples were collected from the animals and their influenza-specific antibody titer was determined using ELISA. Results: The results demonstrated a higher antibody level in treated groups A and B as compared to the control samples. We also showed that the combination of Mx and chitosan could significantly induce an influenza-specific antibody titer, indicating synergistic effects of the applied adjuvant and NPs together. Conclusion: The formulation of H9N2 with Mx as an adjuvant and chitosan as a nanocarrier is a promising procedure for developing an efficient vaccine against avian influenza virus.

show abstract

Improvement influenza HA2 DNA vaccine cellular and humoral immune responses with Mx bio adjuvant

2017

View full text Add to dashboard Cite

In Silico Analysis of HA2/Mx Chimera Peptide for Developing an Adjuvanted Vaccine to Induce Immune Responses Against Influenza Viruses

Cited by 5 publications

References 31 publications

Designing a chimeric subunit vaccine for influenza virus, based on HA2, M2e and CTxB: a bioinformatics study

Designing a chimeric subunit vaccine for influenza virus, based on HA2, M2e and CTxB: a bioinformatics study

Combination of Chitosan and Myxovirus Resistance Oligonucleotide: An Efficient and Safe Natural Adjuvant against Influenza Virus

Improvement influenza HA2 DNA vaccine cellular and humoral immune responses with Mx bio adjuvant

Contact Info

Product

Resources

About